Price
Target price
€3.89
€3.89
-1.590%
-0.064
-1.590%
€5.98
09.06.25 / Tradegate
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Xeris Biopharma Holdings Inc. Stock
We can see a decrease in the price for Xeris Biopharma Holdings Inc.. Compared to yesterday it has lost -€0.064 (-1.590%).
With 7 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 5 € shows a positive potential of 28.47% compared to the current price of 3.89 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -1.590% | -11.706% | -12.461% | 80.019% | 18.731% | 85.025% | -15.022% |
| Krystal Biotech | 0.620% | 9.817% | 2.471% | -20.992% | -20.992% | 135.784% | - |
| Ardelyx Inc. | 4.280% | -3.988% | 0.186% | -46.035% | -35.025% | 412.470% | -50.369% |
| Evolus Inc | -0.610% | -2.941% | -6.780% | -25.000% | -21.429% | -27.632% | 55.660% |
Comments
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $6.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Leerink Partners from $5.00 to $6.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at Craig Hallum from $5.00 to $6.50. They now have a "buy" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
